Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) Digital Int...
August 20 2020 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced that
clinical data from Enanta’s wholly-owned development programs for
non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV)
have been accepted for presentations at the European Association
for the Study of the Liver (EASL) Digital International Liver
Congress 2020 being held August 27-29, 2020.
Clinical data will include an oral presentation of the Phase 2a
ARGON-1 study of EDP-305, Enanta’s Farnesoid X receptor (FXR)
agonist for the treatment of NASH, as well as a poster on new Phase
1 data of EDP-514, Enanta’s core inhibitor for HBV. Preclinical
data on EDP-297, Enanta’s follow-on FXR agonist for NASH, will also
be highlighted in two poster presentations.
The full scientific program for The Digital International Liver
Congress 2020, as well as the abstracts, can be found at
https://ilc-congress.eu/programme-digital-ilc-2020/. Further
details will be available at the time of these presentations.
Oral Presentation: August 28, 2020,
12:15 - 12:30 CEST AS078: “EDP-305, A Non-Bile
Acid Farnesoid X Receptor (FXR) Agonist, Showed Statistically
Significant Improvements in Liver Biochemistry and Hepatic
Steatosis in the Phase 2a ARGON-1 Study” Location: Channel 3
Presenter: Vlad Ratziu, M.D., Ph.D., France
Poster Presentations: August 28,
2020, 09:30 - 19:30 CEST FRI109: “EDP-297, A Novel and
Potent FXR Agonist, Exhibits Robust Anti-Fibrotic Effects with
Significant Liver Function Improvement in a Rat Model of
Non-Alcoholic Steatohepatitis” Presenter: Mozhdeh Sojoodi,
Ph.D., United States
August 29, 2020, 09:30 - 19:30 CEST
SAT042: “A Novel FXR Agonist EDP-297 Exerts Anti-Inflammatory
and Hepatoprotective Effects in Human Liver 3D Microtissues and in
Rodent Models of Liver Injury and NASH” Presenter: Mary Chau,
Ph.D., United States
August 29, 2020, 09:30 - 19:30 CEST
SAT440: “EDP-514, a Novel Pangenotypic Class II Hepatitis B
Virus Core Inhibitor: Final Results of a Phase 1 Study in Healthy
Adult Subjects” Presenter: Kajal Larson, Ph.D., United
States
About Enanta
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections and liver diseases. Enanta’s research and development
efforts have produced clinical candidates for the following disease
targets: respiratory syncytial virus (RSV), non-alcoholic
steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also
conducting research in human metapneumovirus (hMPV) and SARS-CoV-2
(COVID-19).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200820005185/en/
Investors Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024